2006
DOI: 10.3132/dvdr.2006.020
|View full text |Cite
|
Sign up to set email alerts
|

Ezetimibe added to ongoing statin therapy improves LDL-C goal attainment and lipid profile in patients with diabetes or metabolic syndrome

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

12
55
0
1

Year Published

2008
2008
2023
2023

Publication Types

Select...
4
2

Relationship

1
5

Authors

Journals

citations
Cited by 67 publications
(68 citation statements)
references
References 66 publications
12
55
0
1
Order By: Relevance
“…Adding ezetimibe to ongoing statin therapy significantly reduces ApoB levels compared with placebo in metabolic syndrome and T2DM patients, respectively (-13.2 and -18.1%; p < 0.001) [68]. The ratio of ApoB/ApoAI, thought to be one of the most correlative predictors of CVD risk [88], was significantly reduced by the addition of ezetimibe compared with placebo to ongoing statin therapy in both metabolic syndrome and T2DM patients (-16.6 and -17.7%; p < 0.001) [69].…”
Section: Apob-100mentioning
confidence: 89%
See 4 more Smart Citations
“…Adding ezetimibe to ongoing statin therapy significantly reduces ApoB levels compared with placebo in metabolic syndrome and T2DM patients, respectively (-13.2 and -18.1%; p < 0.001) [68]. The ratio of ApoB/ApoAI, thought to be one of the most correlative predictors of CVD risk [88], was significantly reduced by the addition of ezetimibe compared with placebo to ongoing statin therapy in both metabolic syndrome and T2DM patients (-16.6 and -17.7%; p < 0.001) [69].…”
Section: Apob-100mentioning
confidence: 89%
“…When added to stable, ongoing statin therapy, ezetimibe significantly increased HDL levels in patients with metabolic syndrome by 2.6% (p < 0.05), versus placebo addition, and provided comparable HDL-C increases in T2DM patients [68]. In another study, ezetimibe added to ongoing statin therapy significantly increased levels of HDL-C by 2.8 and 2.7%, compared with placebo (p = 0.002 and p < 0.001) in patients with metabolic syndrome and T2DM, respectively [69]. Treatment with ezetimibe/simvastatin 10/20 mg significantly increased HDL-C levels by 3.6 and 3.4% more than atorvastatin 10 and 20 mg (p ≤ 0.001), and with ezetimibe 10/40 mg by 4.0% versus atorvastatin 40 mg (p < 0.001) in T2DM patients [70].…”
Section: Hdl Cholesterolmentioning
confidence: 92%
See 3 more Smart Citations